Roger M. Boissonneault was appointed Chief Executive Officer, President and Director of Warner Chilcott as of January 5, 2005. Mr. Boissonneault was appointed Chief Executive Officer and Director of one of Warner Chilcott’s predecessors in September 2000. From 1996 to 2000, he served as President and Chief Operating Officer of the company acquired by Warner Chilcott’s predecessor, which was also known as Warner Chilcott PLC, serving as a director from 1998 through 2000. From 1976 to 1996, Mr. Boissonneault served in various capacities with Warner-Lambert (now a part of Pfizer), including as Vice President, Female Healthcare, Director of Corporate Strategic Planning and Director of Obstetrics/Gynecology Marketing.

Paul Herendeen joined Warner Chilcott as Chief Financial Officer and Executive Vice President on April 1, 2005 and is responsible for finance, accounting and treasury functions. Mr. Herendeen was appointed as a Director of Warner Chilcott in May 2013.  From April 2001 to March 2005, Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. From 1998 through March 2001, Mr. Herendeen served as our Executive Vice President and Chief Financial Officer. Mr. Herendeen also served as a director of our predecessor companies from 1996 through March 2001.

Leland H. Cross joined Warner Chilcott as a Senior Vice President on September 1, 2001 and is responsible for technical operations worldwide. From 1994 to 2001, Mr. Cross was part of the Global Manufacturing group at Warner-Lambert (now part of Pfizer), where most recently he was General Manager of Pfizer Ireland Pharmaceuticals, responsible for Pfizer's dosage manufacturing operations in Ireland. Prior to joining Warner-Lambert, Mr. Cross managed a manufacturing operation for Merck & Co. Inc.

Herman Ellman, M.D., joined Warner Chilcott as Senior Vice President, Clinical Development in June 2000. Dr. Ellman is responsible for clinical development and medical affairs activities. Prior to joining Warner Chilcott, Dr. Ellman held the position of Medical Director for Women's Healthcare at Berlex Laboratories.

Andrew Fenton currently serves as Senior Vice President, Chief Information Officer for Warner Chilcott and is responsible for our information technology strategy, infrastructure and operations. Mr. Fenton joined Warner Chilcott in November 2005 and held positions of increasing responsibility before his promotion to Senior Vice President in January 2012, including most recently, Vice President, Chief Information Officer. Prior to joining Warner Chilcott, Mr. Fenton held various positions in information technology at IBM Corporation, including most recently, Vice President, Global Relationship Partner.

Claire A. Gilligan, Ph.D. currently serves as Senior Vice President, Quality for Warner Chilcott and is responsible for quality worldwide. Dr. Gilligan joined a predecessor of Warner Chilcott in 1992 and has held positions of increasing responsibility at Warner Chilcott since that time. From 2004 until her promotion to Senior Vice President in July 2010, Dr. Gilligan was Vice President of Pharmaceutical Development, during which time she was responsible for the development of all products and manufacturing processes. Prior to joining Warner Chilcott, Dr. Gilligan lectured in the School of Pharmacy at the Queen’s University of Belfast.

Alvin D. Howard joined Warner Chilcott as Vice President, Regulatory Affairs in February 2001. He was promoted to Senior Vice President as of August 1, 2005 and is responsible for the registration of all products and for managing relationships with the U.S. Food and Drug Administration, Health Canada and other agencies regulating the sale of pharmaceutical products. Prior to joining Warner Chilcott, Mr. Howard was Vice President, Worldwide Regulatory Affairs at Roberts Pharmaceuticals.

Francisco Rodriguez Rama has served as Senior Vice President, Technical Operations for Warner Chilcott since February 2013 and is responsible for the technical operations of Warner Chilcott’s manufacturing facilities in Fajardo, Puerto Rico, Weiterstadt, Germany and Larne, Northern Ireland. Mr. Rodriguez joined Warner Chilcott in March 2011 as General Manager of Warner Chilcott’s Fajardo, Puerto Rico manufacturing facility. Prior to joining Warner Chilcott, Mr. Rodriguez served as Vice President of Operations at Cephalon, Inc. from 2008 to 2011. Prior to joining Cephalon, Inc., Mr. Rodriguez worked for over 20 years in Schering-Plough Corporation’s (now Merck & Co., Inc.) product supply organization in positions of increasing responsibility.

Ryan T. Sullivan currently serves as Vice President, General Counsel and Secretary for Warner Chilcott and is responsible for Warner Chilcott’s legal matters.  Mr. Sullivan joined Warner Chilcott’s legal group in July 2007 and held positions of increasing responsibility before his promotion to his current position in September 2012.  Prior to joining Warner Chilcott, Mr. Sullivan practiced law in the corporate group of Cahill Gordon & Reindel LLP.

L. Stephan Vincze joined Warner Chilcott as Senior Vice President, Chief Compliance Officer in May 2013 and is responsible for Warner Chilcott’s compliance function.  Prior to joining Warner Chilcott, Mr. Vincze held various positions at Deloitte & Touche LLP from 2008 to 2013, most recently Director, Health Care Compliance Advisory Services/Governance, Regulatory and Risk Strategies.  Prior to joining Deloitte & Touche LLP, Mr. Vincze served as Vice President, Chief Ethics and Compliance Officer/Privacy Officer at TAP Pharmaceutical Products, Inc.